Patents by Inventor Rex M. Bitner
Rex M. Bitner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160333396Abstract: Compositions, methods and kits for determination of the nucleic acid amplification status of nucleic acid samples, and analysis of other high copy nucleic acid products, are disclosed, as well as a matrix and method for storage of nucleic acid amplification products. In a preferred embodiment, the method provides for a determination of whether or not a nucleic acid amplification reaction has produced an anticipated product, or not, and provides, without the use of electricity, a visual readout detectable with the unaided human eye.Type: ApplicationFiled: May 15, 2015Publication date: November 17, 2016Inventors: Rex M. Bitner, Tonny M. Johnson
-
Patent number: 8658360Abstract: The present invention relates to methods, kits, and compositions for generating purified RNA samples and purified DNA samples. In particular, the present invention provides methods for generating a purified RNA or DNA sample from a sample containing both DNA and RNA molecules using a binding matrix that preferentially binds DNA or RNA in the presence of an acidic dilution buffer, or using a binding matrix that comprises acid zeolites, as well as compositions and kits for practicing such methods.Type: GrantFiled: September 1, 2011Date of Patent: February 25, 2014Assignee: Promega CorporationInventors: Rex M. Bitner, Michelle M. Mandreker, Paula R. Brisco
-
Patent number: 8519119Abstract: A formulation containing guanidine thiocyanate or guanidine hydrochloride together with acetamide, one or more acetamide derivatives, or a combination of acetamide and one or more acetamide derivatives is provided with methods to use the formulation to purify one or more nucleic acids contained in a medium.Type: GrantFiled: September 14, 2011Date of Patent: August 27, 2013Assignee: Promega CorporationInventor: Rex M. Bitner
-
Publication number: 20120309952Abstract: The present invention relates to methods, kits, and compositions for purifying small RNA molecules. In particular, the present invention provides methods for purifying small RNA molecules from a sample containing both small RNA molecules and larger RNA molecules using a compaction agent and a RNA binding matrix, as well as compositions and kits for practicing such methods. In certain embodiments, the compaction agent comprises a plurality of metal-amine-halide molecules.Type: ApplicationFiled: July 17, 2012Publication date: December 6, 2012Applicant: PROMEGA CORPORATIONInventors: Rex M. Bitner, Mark A. Denhart, Donald B. Smith
-
Patent number: 8222397Abstract: A method and kit which allow the use of a discrete amount of a binding matrix to first purify nucleic acids from a medium under a first set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially independent of the amount of surface area of the definable amount of the binding matrix, followed by a second purification step wherein the nucleic acids are bound to a discrete amount of binding matrix under a second set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially dependent on the amount of surface area of the definable amount of the binding matrix, thus providing a discrete quantity of nucleic acid.Type: GrantFiled: August 28, 2009Date of Patent: July 17, 2012Assignee: Promega CorporationInventor: Rex M. Bitner
-
Publication number: 20120059160Abstract: The present invention relates to methods, kits, and compositions for generating purified RNA samples and purified DNA samples. In particular, the present invention provides methods for generating a purified RNA or DNA sample from a sample containing both DNA and RNA molecules using a binding matrix that preferentially binds DNA or RNA in the presence of an acidic dilution buffer, or using a binding matrix that comprises acid zeolites, as well as compositions and kits for practicing such methods.Type: ApplicationFiled: September 1, 2011Publication date: March 8, 2012Applicant: PROMEGA CORPORATIONInventors: Rex M. Bitner, Michelle M. Mandreker, Paula R. Brisco
-
Publication number: 20120022247Abstract: A formulation containing guanidine thiocyanate together with acetamide, one or more acetamide derivatives, or a combination of acetamide and one or more acetamide derivatives is used to purify one or more nucleic acids contained in a medium. In particular, a medium containing at least one nucleic acid is combined with a binding matrix and the formulation in order to cause the at least one nucleic acid to separate from its in vivo cellular environment and to bind to the binding matrix. The binding matrix with at least one nucleic acid bound thereto then is separated from substantially the rest of the combined medium and formulation, after which the at least one nucleic acid is eluted from the binding matrix to obtain the at least one nucleic acid in a substantially purified form.Type: ApplicationFiled: September 14, 2011Publication date: January 26, 2012Inventor: Rex M. Bitner
-
Patent number: 8039613Abstract: A formulation containing guanidine thiocyanate together with acetamide, one or more acetamide derivatives, or a combination of acetamide and one or more acetamide derivatives is used to purify one or more nucleic acids contained in a medium. In particular, a medium containing at least one nucleic acid is combined with a binding matrix and the formulation in order to cause the at least one nucleic acid to separate from its in vivo cellular environment and to bind to the binding matrix. The binding matrix with at least one nucleic acid bound thereto then is separated from substantially the rest of the combined medium and formulation, after which the at least one nucleic acid is eluted from the binding matrix to obtain the at least one nucleic acid in a substantially purified form. If different nucleic acids are to be selectively purified from a single medium, multiple binding matrices, each compatible with a different nucleic acid, can be used.Type: GrantFiled: August 28, 2009Date of Patent: October 18, 2011Assignee: Promega CorporationInventor: Rex M. Bitner
-
Patent number: 8030034Abstract: The present invention relates to methods, kits, and compositions for generating purified RNA samples and purified DNA samples. In particular, the present invention provides methods for generating a purified RNA or DNA sample from a sample containing both DNA and RNA molecules using a binding matrix that preferentially binds DNA or RNA in the presence of an acidic dilution buffer, or using a binding matrix that comprises acid zeolites, as well as compositions and kits for practicing such methods.Type: GrantFiled: December 8, 2006Date of Patent: October 4, 2011Assignee: Promega CorporationInventors: Rex M. Bitner, Michelle N. Mandrekar, Paula R. Brisco
-
Publication number: 20110054157Abstract: A method and kit which allow the use of a discrete amount of a binding matrix to first purify nucleic acids from a medium under a first set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially independent of the amount of surface area of the definable amount of the binding matrix, followed by a second purification step wherein the nucleic acids are bound to a discrete amount of binding matrix under a second set of binding conditions wherein the amount of nucleic acid bound to the binding matrix is essentially dependent on the amount of surface area of the definable amount of the binding matrix, thus providing a discrete quantity of nucleic acid.Type: ApplicationFiled: August 28, 2009Publication date: March 3, 2011Applicant: PROMEGA CORPORATIONInventor: Rex M. Bitner
-
Publication number: 20110054161Abstract: A formulation containing guanidine thiocyanate together with acetamide, one or more acetamide derivatives, or a combination of acetamide and one or more acetamide derivatives is used to purify one or more nucleic acids contained in a medium. In particular, a medium containing at least one nucleic acid is combined with a binding matrix and the formulation in order to cause the at least one nucleic acid to separate from its in vivo cellular environment and to bind to the binding matrix. The binding matrix with at least one nucleic acid bound thereto then is separated from substantially the rest of the combined medium and formulation, after which the at least one nucleic acid is eluted from the binding matrix to obtain the at least one nucleic acid in a substantially purified form. If different nucleic acids are to be selectively purified from a single medium, multiple binding matrices, each compatible with a different nucleic acid, can be used.Type: ApplicationFiled: August 28, 2009Publication date: March 3, 2011Applicant: PROMEGA CORPORATIONInventor: Rex M. Bitner
-
Publication number: 20100143878Abstract: Disclosed are methods for differential extraction of a target component from a sample which is predominantly composed of other types of non-target cells that can be lysed using methods that do not lyse the target cells, so that the target material can be purified away from the lysed non-target material. One exemplary method is directed to isolating sperm cells from an aqueous sample and kits for performing same.Type: ApplicationFiled: October 8, 2007Publication date: June 10, 2010Applicant: PROMEGA CORPORATIONInventors: Ryan J. Olson, Rex M. Bitner, Allan M. Tereba, Laura L. Bozek
-
Patent number: 7078224Abstract: Methods are disclosed for using paramagnetic particles to concentrate or harvest cells. Methods are also disclosed for clearing a solution of disrupted biological material, such as a lysate of cells or a homogenate of mammalian tissue. Methods are also disclosed for using paramagnetic particles to isolate target nucleic acids, such as RNA or DNA, from a solution cleared of disrupted biological material using the same type or a different type of paramagnetic particle. Kits are also disclosed for use with the various methods of the present invention. Nucleic acids isolated according to the present methods and using the present kits are suitable for immediate use in downstream processing, without further purification.Type: GrantFiled: December 30, 1999Date of Patent: July 18, 2006Assignee: Promega CorporationInventors: Rex M. Bitner, Craig E. Smith, Douglas H. White, Braeden L. Butler, Jacqui Sankbeil
-
Patent number: 6806362Abstract: Disclosed are pH dependent ion exchange matrices, methods of making, and methods of use.Type: GrantFiled: March 20, 2001Date of Patent: October 19, 2004Assignee: Promega CorporationInventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzenhendler, Rex M. Bitner, Josephine C. Grosch
-
Patent number: 6787307Abstract: A method is provided for using a silanized silica matrix to isolate a target nucleic acids, such as plasmid DNA, fragments of DNA, chromosomal DNA, or RNA from contaminants, including proteins, lipids, cellular debris, or non-target nucleic acids. The silanized silica matrix comprises a silica based solid phase and a plurality of silane ligands covalently attached to the surface of the solid phase. Non-target material adsorbs to the silanized silica matrix in the presence of a sufficient concentration of chaotropic salt, while target nucleic acids adsorb to the matrix under other solution conditions. The method of using the silanized silica matrix of the present invention can be used to clear solutions of disrupted biological material, and to isolate nucleic acids therefrom or from other solutions containing nucleic acids and at least one contaminant.Type: GrantFiled: November 13, 2000Date of Patent: September 7, 2004Assignee: Promega CorporationInventors: Rex M. Bitner, Daniel J. Simpson, Roderick G. Flemming, Susan C. Koller
-
Publication number: 20040086930Abstract: The present invention provides methods for isolating a defined quantity of DNA target material from other substances in a medium. The method may be carried out using a known quantity of a silica-containing solid support, such as silica magnetic particles, having a definable capacity for reversibly binding DNA target material, and DNA target material in excess of the binding capacity of the particles. The methods of the present invention involve forming a complex of the silica magnetic particles and the DNA target material in a mixture of the medium and particles, and separating the complex from the mixture using external magnetic force. The DNA target material may then be eluted from the complex. The quantity of DNA target material eluted may be determined based on a calibration model. The methods of the present invention permit isolation of DNA target material which is within a known quantity range.Type: ApplicationFiled: October 27, 2003Publication date: May 6, 2004Applicant: Promega CorporationInventors: Allan M. Tereba, Rex M. Bitner, Susan C. Koller, Craig E. Smith, Daniel D. Kephart, Steven J. Ekenberg
-
Patent number: 6673631Abstract: The present invention provides methods for isolating a defined quantity of DNA target material from other substances in a medium. The method may be carried out using a known quantity of a silica-containing solid support, such as silica magnetic particles, having a definable capacity for reversibly binding DNA target material, and DNA target material in excess of the binding capacity of the particles. The methods of the present invention involve forming a complex of the silica magnetic particles and the DNA target material in a mixture of the medium and particles, and separating the complex from the mixture using external magnetic force. The DNA target material may then be eluted from the complex. The quantity of DNA target material eluted may be determined based on a calibration model. The methods of the present invention permit isolation of DNA target material which is within a known quantity range.Type: GrantFiled: August 20, 1999Date of Patent: January 6, 2004Assignee: Promega CorporationInventors: Allan M. Tereba, Rex M. Bitner, Susan C. Koller, Craig E. Smith, Daniel D. Kephart, Steven J. Ekenberg
-
Patent number: 6376194Abstract: Mixed-bed solid phases are provided, with methods for using such solid phases to isolate target nucleic acids, such as plasmid DNA, chromosomal DNA, RNA, or nucleic acids generated by enzymatic amplification from contaminants, including proteins, lipids, cellular debris, or other nucleic acids. The mixed-bed solid phases of this invention are mixtures of at least two different solid phases, each of which has a capacity to bind to the target nucleic acid under different solution conditions, and the capacity to release the nucleic acid under similar elution conditions. By exchanging solution conditions according to the methods of this invention, one can remove contaminants from the target nucleic acid bound to the mixed-bed solid phase, then elute the target nucleic acid in an elution buffer.Type: GrantFiled: July 24, 2001Date of Patent: April 23, 2002Assignee: Promega CorporationInventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzenhendler, Rex M. Bitner, Josephine C. Grosch
-
Publication number: 20020001812Abstract: Mixed-bed solid phases are provided, with methods for using such solid phases to isolate target nucleic acids, such as plasmid DNA, chromosomal DNA, RNA, or nucleic acids generated by enzymatic amplification from contaminants, including proteins, lipids, cellular debris, or other nucleic acids. The mixed-bed solid phases of this invention are mixtures of at least two different solid phases, each of which has a capacity to bind to the target nucleic acid under different solution conditions, and the capacity to release the nucleic acid under similar elution conditions. By exchanging solution conditions according to the methods of this invention, one can remove contaminants from the target nucleic acid bound to the mixed-bed solid phase, then elute the target nucleic acid in an elution buffer.Type: ApplicationFiled: July 24, 2001Publication date: January 3, 2002Applicant: Promega Corporation.Inventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzhendler, Rex M. Bitner, Josephine C. Grosch
-
Patent number: 6310199Abstract: pH dependent ion exchange matrices are provided, with methods for making such matrices, and methods for using such matrices to isolate a target nucleic acid, such as plasmid DNA, chromosomal DNA, or RNA from contaminants, including proteins, lipids, cellular debris, or other nucleic acids. Each pH dependent ion exchange matrix of this invention comprises at least two different ion exchange functional groups, one of which is capable of acting as an anion exchanger at a first pH, and the other of which is capable of acting as a cation exchanger at a second, higher pH. The matrix has an overall neutral charge in a pH range between the first and second pH. The pH dependent ion exchange matrices of the present invention are designed to bind to the target nucleic acid at a pH wherein the overall charge of the matrix is positive, and to release the target nucleic acid as the pH of the surrounding solution is increased.Type: GrantFiled: May 14, 1999Date of Patent: October 30, 2001Assignee: Promega CorporationInventors: Craig E. Smith, Diana L. Holmes, Daniel J. Simpson, Jehoshua Katzenhendler, Rex M. Bitner, Josephine C. Grosch